Ovarian Cancer

Topline results reported from the UPLIFT trial showed it did not meet its primary end point of objective response rate in the NaPi2b-positive population with ovarian cancer.

During a Targeted Oncology™ Clinical Case Forum™ event, Lyndsay Willmott, MD, discussed the data supporting the use of PARP inhibitors as primary maintenance therapy for patients with ovarian cancer.

Niraparib as a monotherapy is supported as standard of care for a broad patient population with advanced ovarian cancer after first-line platinum-based chemotherapy.

Christina Fotopoulou, MD, PhD, discusses the results of the DUO-O trial in patients with newly diagnosed ovarian cancer.

Leslie Randall, MD, MAS, offers closing thoughts on the future trajectory of ovarian cancer treatment.

An expert gynecologic oncologist comments on recent revisions to FDA-approved indications for PARP inhibitors in the treatment of ovarian cancer.

Leslie Randall, MD, MAS, reviews recent long-term data on PARP inhibitors in the treatment of ovarian cancer.

Clinical insights on how to manage adverse events for patients with ovarian cancer who are receiving PARP inhibitors.

An expert on ovarian cancer discusses factors that influence PARP inhibitor selection, when to initiate maintenance therapy, and how to counsel patients on PARP inhibitors.

Leslie Randall, MD, MAS, reviews the available treatment options for BRCA-mutated advanced ovarian cancer.

An overview of guideline recommendations for molecular testing in ovarian cancer.

Leslie Randall, MD, MAS, presents the case of a 55-year-old woman with BRCA-mutated ovarian cancer and provides her initial impressions.

The combination of avutometinib with defactinib elicited high activity in patients with recurrent low-grade serous ovarian cancer, according to data from RAMP 201.

The use of maintenance niraparib therapy led to clinically meaningful improvement in progression-free survival, compared with placebo, in patients with newly diagnosed, advanced ovarian cancer.

Second-line maintenance therapy with niraparib improved overall survival in a BRCA gene wild-type population with recurrent ovarian cancer.

Kathleen N. Moore, MD says the phase 3 MIRASOL results bring a new standard-of-care to the FRα-high, platinum-resistant ovarian cancer landscape.

Phase 3 DUO-O study results reveal a promising strategy for patients with HRD-negative advanced ovarian cancer.

Bruno Bockorny, MD, discusses the phase 1 C-800 trial of botensilimab plus bastilimab, specifically for patients in the C-800-01 cohort with recurrent platinum refractory/resistant ovarian cancer.

The approved PARP inhibitor niraparib has been beneficial for patients with recurrent ovarian cancer, but new second-line restrictions for certain patients have led physicians to be more cautious when re-challenging these patients.

ACR-368 generated deep and durable responses across several phase 2 studies. The agent has now been granted fast track designations for patients with platinum-resistant ovarian cancer and endometrial cancer.

In an interview with Targeted Oncology for World Ovarian Cancer Day, Natalie Godbee, DO, discussed the current state of treatment for advanced ovarian cancer and how oncologists can get the best outcomes for their patients.

Impressive efficacy data and consistent safety data continue to be seen with mirvetuximab soravtansine for the treatment of patients with platinum-resistant ovarian cancer, according to data from the confirmatory MIRASOL trial.

Treatment with niraparib elicited durable conditional progression-free survival rates vs placebo in patients with ovarian cancer whose tumors were homologous recombination deficient.

Matthew Anderson, MD, PhD, discusses how the results with niraparib for patients with advanced ovarian cancer impacts the use of somatic profiling in this patient population.

Bruno Bockorny, MD, explains the mechanism of action of botensilimab and its use in combination with balstilimab for ovarian cancer treatment.